Drug Safety Update. Topiramate (Topamax) start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure

The Medicines and Healthcare Regulatory Authority (MHRA) have initiated a new safety review into topiramate as a result of an observational study reporting an increased risk of neurodevelopmental disabilities in children whose mothers took topiramate during pregnancy. Topiramate is known to be associated with an increased risk of congenital malformations and effects on fetal growth if used during pregnancy.

The MHRA have advised to continue to counsel patients who can become pregnant on the known and emerging risks of topiramate for an unborn baby and on the need to use effective contraception throughout use.

Further information and advice for healthcare professionals can be found on the MHRA website